6 Chinese medicine companies disclose the results of 2019 annual report, 3 of which are expected to be happy

[pharmaceutical network industry trends] at present, major listed companies have entered the annual disclosure season As of January 15, there are 48 listed companies whose performance is or will grow in 2019 in the pharmaceutical and biological industry, including 6 companies in the same traditional Chinese medicine industry, and 3 companies, including wohua pharmaceutical, Cr Sanjiu and Taihe health, may achieve a significant increase in performance, and another 3 companies may achieve a turnaround Opportunities and challenges coexist in the traditional Chinese medicine industry In 2019, China issued a series of documents, regulations and measures on traditional Chinese medicine, providing good policy support and financial support for the development of the industry For example, the outline of "healthy China 2030" proposed the implementation of TCM inheritance and innovation project, attached great importance to the study and excavation of TCM classic medical books, comprehensively and systematically inherited the academic theories, schools and theories of previous generations, continuously promoted the academic thoughts and clinical diagnosis and treatment experience of contemporary famous and old TCM experts, excavated folk diagnosis and treatment technologies and prescriptions, and promoted the inheritance and development of TCM culture Driven by a series of national favorable policies, China's traditional Chinese medicine industry ushered in new opportunities for development, and many industry enterprises benefited Take Lingrui pharmaceutical as an example The growth rate of net profit in 2017, 2018 and 2019 was - 37.21%, 11.77% and 23.05% respectively The operating revenue and net profit in 2019 were 1.69 billion yuan and 260 million yuan respectively, exceeding the data of 2017 At the same time, the traditional Chinese medicine industry is also facing a more severe test, the industry needs to be more standardized For example, in the new version of the medical insurance catalog, more than 500 kinds of drugs are restricted in the payment of medical insurance, including some pieces of traditional Chinese medicine, 77 oral Chinese patent medicines, 45 injections of traditional Chinese medicine, etc As an important carrier of traditional Chinese medicine culture, from the supporting documents of 2019 version of national medical insurance catalog and the signals from the supporting policies of provinces (cities), we can see that the traditional Chinese medicine industry will become more and more standardized, and in the future, it will develop rapidly with the progress of traditional Chinese medicine industry At present, the market share of traditional Chinese medicine has been around 20% - 30% The industry believes that under the medical reform system of gradually improving the national medical insurance, in the future, if the number of traditional Chinese medicine varieties entering the basic medicine and medical insurance catalogue increases gradually, it will be conducive to the industrialization of traditional Chinese medicine For those Chinese medicine enterprises with core competitiveness, it is expected to usher in new opportunities The performance of three traditional Chinese medicine companies may increase significantly According to the 2019 performance forecast recently released by wohua pharmaceutical, the annual profit in 2019 is expected to be 89.02 million yuan - 110.4766 million yuan, up 95% - 142% year on year In 2018, the net profit was 45.6515 million yuan As for the reason for the increase in performance, wohua explained that it was due to the significant improvement of the company's refined management level in 2019, which greatly reduced the cost on the premise of ensuring the steady growth of sales revenue In addition, Cr 39 is expected to make a profit of 2.11-2.25 billion yuan in 2019, up 47.34% - 57.11% year on year According to the company, the main reason for the significant increase in performance is that the company completed the sale of 82.89% of its shares in Shenzhen Sanjiu hospital Co., Ltd through public listing transfer in January 2019, bringing the company about 680 million yuan (after tax) asset disposal income, which is non recurring profit and loss Taihe health's profit in 2019 is expected to be between 60 million yuan and 68 million yuan, up 92.5% - 118.16% year on year The company said that the reason for the growth of performance was that during the reporting period, the company continued to strengthen market development and project undertaking, with the sales scale increasing year on year and operating profit increasing year on year Industry insiders believe that in 2019, affected by relevant policies, the overall market of the pharmaceutical industry is relatively stable But if we want to maintain vitality and occupy more market share, we need to continue to improve the core competitiveness of our products.